Replies to post #185213 on Biotech Values

[RockRat]

RE: Celladon:

Thanks for that. I was wondering about this: "There were some imbalances in baseline patient characteristics across the treatment arms in CUPID 1. In particular, there was a higher percentage of healthier patients in Mydicar arms relative to placebo arms. Post-hoc sensitivity analyses though suggested that the differences in baseline patient characteristics could not completely explain the clinical outcomes observed in CUPID 1. "

Celladon is almost at the price target now. Might explore this as a short candidate. A quick EDGAR search shows no bailing by insiders or holders so far, and I assume lockup period is over.

Thanks to PGS for the additional color.

Regards, RockRat